JP2000283985A - Analyzer - Google Patents

Abstract

PROBLEM TO BE SOLVED: To surely carry out re-inspection for a specimen having the possibility affected by carry-over without generating waste in inspection, to shorten an inspection time, to reduce an inspection cost, to enhance reliability for the inspection, and to prevent an inspection error. SOLUTION: This analyzer for analyzing sequentially respective desired measuring items as to plural specimens is provided with a high-value abnormality detecting means 15 for detecting high-value abnormality out of measured values provided in order, and a control means 11 for controlling an analytical operation to execute re-inspection upto a preset number of tests relating to the specimens after the specimen where the abnormality is detected, when the high-value abnormality is detected by the abnormality detecting means 15.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an analyzer such as a biochemical analyzer or an immunoanalyzer for automatically and sequentially analyzing desired measurement items for a plurality of samples.

[0002]

2. Description of the Related Art In an analyzer, for example, samples are sequentially dispensed from a plurality of sample containers accommodating different samples into a reaction container by sample dispensing means, and the reagent dispensed into the reaction container into which the sample has been dispensed. Reagents corresponding to the measurement items are dispensed by the injection means and reacted, the reaction state is measured, and the desired measurement items are quantitatively and qualitatively performed.
Note that the order of dispensing the sample and the reagent may be that of the reagent first. Here, for example, in the sample dispensing means, the sample dispensing nozzle penetrates into the sample to aspirate the sample and dispenses the sample. In order to prevent carryover, the inner and outer walls of the sample dispensing nozzle are washed before dispensing different specimens.

However, since there is a limit in sufficiently washing the sample dispensing nozzle within a predetermined washing time, when a sample showing an abnormally high value is analyzed, carryover to the next sample may occur. is there. In this way, when carryover occurs, the measured value of the sample affected by carryover will not show a true value, so if the effect of carryover on the next sample is concerned, retest Need to be performed.

[0004] Therefore, in order to automatically perform a re-examination due to carry-over, a sample showing an abnormally high value is detected from the obtained measured values, and if an abnormally high value is detected, all samples for the next sample are accepted. Re-examination,
Alternatively, it is conceivable that the retest is performed only on the same measurement item as the measurement item showing an abnormally high value among the measurement items of the next sample.

[0005]

However, if re-examination is performed for all the measurement items for which the next sample has been received, even the measurement items that do not need to be re-examined will be re-examined. There will be waste.
For example, when the measurement items of the first sample are AFP and INS and the measurement items of the second sample are also AFP and INS, and the AFP of the first sample shows a high value abnormality, the retest for the second sample is carried over. AFP threatened by impact
INS will be re-examined,
The inspection is wasted.

If the retest is performed only on the same measurement item as the measurement item showing an abnormally high value, the retest is not performed if the next sample does not have the measurement item. If the next sample contains a substance that affects carry-over in the next sample, the effect of carry-over will be overlooked as a result. For example, when the measurement item of the first sample is AFP and the measurement item of the second sample is CEA, and the AFP of the first sample shows a high value abnormality, there is no AFP in the second sample. Is not subject to re-examination. However, a sample having a high AFP abnormal value has a very high probability that the CEA also has a high value abnormality. Therefore, actually, the measured value of CEA of the next sample is likely to be affected by carryover. For this reason,
As a result, the effects of carryover are overlooked.

Japanese Patent Application Laid-Open No. 5-172828 discloses that in an analyzer that repeatedly uses a reaction vessel after cleaning, in the case of a measurement item in which carry-over is likely to occur, analysis is performed in the same reaction vessel, and The analysis is performed by changing the transfer order of the reaction vessels so that a reagent that is a combination of measurement items that hardly causes carryover is dispensed between measurement items that are likely to cause carryover depending on the combination. Although such a configuration is disclosed, it does not mention re-testing when the effect of carry-over on the next sample is feared.

The present inventor has studied the effects of carryover on the next test, and as a result, has clarified the following. In other words, a sample that gives carry-over causes carry-over from a point when the concentration exceeds a certain concentration, and the carry-over amount given to the next test slightly increases as the concentration value becomes higher than the certain value, but when the concentration value exceeds a certain value, The carry-over amount is almost constant. For example, as shown in Table 1 and FIG. 9, the carry-over amount of AFP indicates that the concentration value of AFP is 13000 ng.
/ Ml, the carry-over amount was 0.9 ng / ml, but even if the concentration value was further increased, the carry-over amount was 1.5 ng / ml at the maximum.

[0009]

[Table 1]

As described above, since the carry-over amount is limited to a certain amount, after analyzing a sample showing a high value abnormality, it is possible to clarify in advance how many tests will be affected.
It was also found that the difference between the measurement items could be clarified. For example, at the current cleaning level of the sample dispensing nozzle in the biochemical analyzer, the effect remains until the next test. Therefore, the retest must be performed until the next test. In addition, at the current washing level of the sample dispensing nozzle in the immunoanalyzer, it was found that the effect of carryover was up to the next test, so that the retest should be performed until the next test.

Further, when a certain measurement item shows a high value abnormality, it is predicted that other measurement items of the biological function related to the measurement item also become high value abnormality, and it is confirmed that such a situation actually occurs. did it. For example, after analyzing a sample with an AFP concentration of 500,000 ng / ml,
When EA was measured, the measured value of CEA showed an increase of 0.5 ng / ml with respect to the known measured value. Similarly, after analyzing a sample having an AFP concentration of 500,000 ng / ml, CA19-9 was measured in the next test.
The measured value of 19-9 is 8 ng / ml with respect to the known measured value.
Was observed. Then, when the concentration of AFP was 500,000 ng / ml and the amount of CEA and CA19-9 was determined, the CEA was 150,000 ng / ml and CA19-9
-9 is 540,000 ng / ml, CEA and CA19-9
Was confirmed to be a sample showing a high value abnormality. This was a specimen of a terminally ill patient from liver cancer, and it is not surprising that such a value is shown.

[0012] The present invention has been made in view of the above points, and it is possible to reliably perform a retest of a sample that is likely to be affected by carryover without wasting the test, thereby shortening the test time. It is another object of the present invention to provide an analyzer capable of reducing the inspection cost and improving the reliability of the inspection and preventing the inspection error.

[0013]

According to a first aspect of the present invention, there is provided an analyzer for sequentially analyzing desired measurement items for a plurality of specimens. High-value abnormality detecting means for detecting an abnormality, and controlling the analysis operation such that when a high-value abnormality is detected by the high-value abnormality detecting means, re-examination is performed up to a preset number of tests on the specimens subsequent to the specimen. And control means.

According to a second aspect of the present invention, in the analyzer of the first aspect, the number of tests for performing the retest is set according to a measurement item.

According to a third aspect of the present invention, in the analyzer according to the first or second aspect, the retest is performed on a measurement item in which a high value abnormality is detected, or on the measurement item and a measurement item related thereto. It is characterized in that it is implemented for

According to a fourth aspect of the present invention, there is provided the analyzer according to the first, second or third aspect, wherein the measured value of the next sample of the same measurement item as the measurement item in which the high value abnormality is detected is determined. The present invention is characterized in that a sample state including the presence / absence of carryover is determined based on a measured value in a retest of a sample and a reference value for the measurement item.

[0017]

Embodiments of the present invention will be described below with reference to the drawings. FIG. 1 diagrammatically shows the configuration of an analyzer according to the present invention. This analyzer comprises a reaction table 2 for holding a plurality of reaction vessels 1 at equal intervals on the same circumference, and a reagent component disposed around the reaction table 2 so as to function with respect to the reaction vessels 1. It has a pouring section 3, a sample dispensing section 4, a stirring section 5, a washing section 6, a photometric section 7, and a reaction vessel replacing section 8. The reagent dispensing section 3 and the sample dispensing section 4 respectively include nozzle cleaning tanks 3a and 4 for cleaning the reagent dispensing nozzle and the sample dispensing nozzle (both not shown) prior to dispensing.
The stirring section 5 has a washing tank 5a for washing a stirring rod (not shown) prior to stirring, and the washing section 6 sucks the reaction solution in the reaction vessel 1. And a washing tank 6a of a washing nozzle (not shown) for dispensing and sucking a washing solution into the reaction vessel 1.

The operation of each part including the rotation operation of the reaction table 2 is controlled by the CPU 11 constituting the control means according to the analysis principle, whereby the predetermined measurement item of each sample is The measured values are output to an output unit 12 including a display and a printer. The CPU 11 is connected to an input unit 13 for inputting various information such as measurement items and the like, and is connected to a storage unit 14 for storing an analysis operation program, a worksheet described later, a retest list, and the like. Also, CP
U11 is a high-value abnormality detecting means 1 for detecting a high-value abnormality from measured values sequentially obtained based on an output signal from the photometric unit 7.
Five.

For example, the high value abnormality detecting means 15 determines whether the obtained measured value is a reference value set in advance for the measurement item, for example, an absorbance value indicating the maximum concentration value guaranteed by the calibration curve (the photometric unit 7 generates a color value). Is detected), or when it exceeds the luminescence value (when the photometric unit 7 detects luminescence), it is configured to detect a high value abnormality, or when an extremely high sample value is detected, If the prozone detection logic is used to detect a high value abnormality when a prozone phenomenon is detected, or if the photometric unit 7 is configured to perform two-wavelength absorbance photometry,
It can be arbitrarily configured according to the configuration of the photometric unit 7 and the form of the detected high-value abnormality, such as detecting a high-value abnormality when the measured value at the sub-wavelength exceeds a preset reference value. When a high value abnormality is detected by the high value abnormality detection means 15, a high value abnormality error mark is added to the measured value.

FIG. 2 is a flowchart showing an example of a basic analysis operation when the analyzer shown in FIG. 1 is configured as an immune analyzer. In this immunoanalyzer, while the reaction table 2 is step-moved, for example, in the direction of the arrow, for each reaction container 1, at the first rotation of the reaction table 2, first, the antigen or the antigen corresponding to the measurement item in the reagent dispensing section 3. Dispensing a solid phase reagent containing antibody-fixed microparticles,
Next, a sample such as serum is dispensed from a sample container (not shown) by the sample dispensing section 4 and then stirred by the stirring section 5. Thereafter, the plate is washed with a washing unit 6 to separate an antibody or an antigen bound to the solid phase reagent by an antigen-antibody reaction from a substance that is not bound.
A second B / F separation is performed.

Next, in the second rotation, a labeling reagent in which a luminescent or chromogenic labeling substance is immobilized on the same antigen or antibody as the measurement item is dispensed in the reagent dispensing section 3, followed by stirring in the stirring section 5. Then, the second B / F separation is performed by washing in the washing unit 6.

Further, at the third rotation, the substrate solution for causing the labeling substance to emit or develop a color in the reagent dispensing section 3 is dispensed, stirred by the stirring section 5 and then measured by the photometry section 7. Then, after washing in the washing unit 6 to empty the reaction vessel 1,
The reaction vessel is replaced with a new reaction vessel in the reaction vessel replacing section 8. Therefore, in this immunoassay apparatus, the analysis of the desired measurement item is completed when each reaction container 1 makes three rounds starting from the reagent dispensing section 3.

FIG. 3 is a flowchart showing an example of a basic analysis operation when the analyzer shown in FIG. 1 is configured as a biochemical analyzer. In this biochemical analyzer,
While stepwise moving the reaction table 2 in the direction of the arrow, for example, the reagent dispensing section 3 first dispenses a reagent corresponding to the measurement item to each reaction vessel 1, and then the sample dispensing section 4 removes the reagent from the sample container. After dispensing a sample such as serum, the stirring unit 5
And then the photometry unit 7 performs photometry. Thereafter, the reaction vessel 1 is emptied by washing in the washing section 6 and then selectively exchanged with a new reaction vessel in the reaction vessel exchange section 8. Therefore, in this biochemical analyzer, the analysis of a desired measurement item is completed when each reaction vessel 1 makes one round from the reagent dispensing section 3 as a starting point.

In the biochemical analyzer, the dispensing of the first reagent in the reagent dispensing section 3, the sample dispensing in the sample dispensing section 4, and the stirring in the stirring section 5 are performed at the first rotation. Do,
Thereafter, the second reagent is dispensed in the reagent dispensing section 3 at the second rotation without performing the washing operation in the washing section 6, and the color reaction is measured by the photometry section 7. May be configured to complete the analysis of a desired measurement item by making two rounds from the reagent dispensing unit 3 as a starting point. Also,
In the immunoanalyzer or the biochemical analyzer, the reaction table 2 is rotated by (one round + 1 reaction container) to perform reagent dispensing, sample dispensing, etc., while performing photometry every time the light passes through the photometric unit 7. In some cases, a desired measurement item is analyzed by a late assay method.

In the embodiment of the present invention, the CPU 11 creates a worksheet for re-examination of inspection items due to carryover based on the input information from the input unit 13 and stores the worksheet in the storage unit 14. When a sample is detected, only a specific measurement item of a specific sample is registered in the retest list of the storage unit 14 based on the worksheet, and a retest process is automatically performed.

The process of creating a worksheet and registering it in the reexamination list will be described below. FIG. 4 is a diagram for explaining a worksheet creation process. First, an item Xa that may cause carryover is set in advance, and the set item Xa may be affected by carryover. The item Xb having the property is set. Next, for the set item Xb, the test order α (affected if within the α test order) is set in advance from the sample showing the high value abnormality, and the α for each set item Xb is set. The maximum value αmax of the value is set as the number of tests to be retested.

FIG. 5 is a flowchart showing a registration process to the retest list. For example, if a high value abnormality is detected in the item Xan of the sample 1 (step S1), the process from the worksheet to the α test of the sample 2, ie, α = MAX (αb1: αb
n) is extracted as a retest target (step S2).
Next, after the count value Z of the number of tests is initialized (step S3), it is incremented (step S4), and it is determined whether or not the item of the Z test of the sample 2 is Xbn (step S5). In this case, it is determined whether or not αbn ≧ Z (step S6). If αbn ≧ Z, it is determined whether or not the item Xbn is normally measured in the sample 1 (step S7), and the measurement is performed normally. If not, it is registered in the reexamination list (step S8). Thereafter, it is determined whether or not Z = α (step S9). If Z ≠ α, the process returns to step S4 and repeats the above processing. When Z = α, the registration processing to the reexamination list ends (step S9). Step S1
0). It should be noted that when the determination result in step S5 and step S6 is NO, or when the determination result in step S7 is YE
In the case of S, the process proceeds to step S9 without registering in the reexamination list.

As a result of the registration processing in the retest list, items other than the specified item Xb among the number of tests to be retested, the test order α affected by carryover α
Measurement items that are out of range and measurement items that are measured normally in abnormally high samples are excluded from retesting, and only specific measurement items of specific samples are registered in the retest list and automatically retested. Is done. The measurement value of the inspection measurement item registered in the reinspection list is provided with a reinspection target warning mark indicating that the measurement value is a reinspection object.

In the worksheet shown in FIG. 4, items Xa that may cause carryover, items Xb that may be affected by carryover, test order α that is affected, and the number of tests to be retested αmax However, as shown in FIG. 6, for all the measurement items to be analyzed in advance, a work for registering only a specific sample or a measurement item in the retest list when a sample having a high value abnormality is detected is performed. You can also create a sheet.

FIG. 7 is a flowchart showing a process of registering a retest list based on the worksheet shown in FIG. First, when a high value abnormality is detected in the item Xan of the sample 1 (step S11), it is determined whether or not the number of retests y corresponding to the item Xan is y ≠ 0 (step S12).
If y ≠ 0, the test value count value Z is initialized (step S13), then incremented (step S14), and the item Xbn of the Z test of the sample 2 is set to α (Xa
n, Xbn) ≧ Z (step S15), and α
When (Xan, Xbn) ≧ Z, it is determined whether or not the item Xbn is normally measured in the sample 1 (step S).
16) If the measurement is not performed normally, register it in the retest list (step S17). Thereafter, it is determined whether or not Z = y (step S18). If Z ≠ y, step S is performed.
14 and repeats the above processing. When Z = y is reached, the registration processing to the retest list is terminated, and the analysis operation in the retest mode is performed (step S19). If the result of the determination in step S15 is NO, or if the result of the determination in step S16 is YES, the process proceeds to step S18 without registering in the reexamination list. If y = 0 in step S12, the analysis operation ends without performing the reinspection process (step S20).

As described above, if only specific samples or measurement items are registered in the retest list based on the worksheet shown in FIG. 6, more flexible settings can be made when extracting retest items. .

When it is known how much the value fluctuates under the influence of carry-over, the value is stored in advance as a reference value, and the next test measurement value of the high value abnormal sample and The retest measurement value and the reference value may provide information on the retest measurement value or the high-value abnormal sample. If the test to which the re-test target warning mark is given is also given the high-value abnormal error mark at the same time, for example, the high-value abnormal error mark is prioritized in any item, and the processing by the re-test target warning mark is canceled. . This is because, regarding the carryover that can be considered at present, even if the carryover effect occurs in the high-value abnormal sample, the carryover effect falls within the range of measurement variation and hides the influence. In the future,
In such a case, when a measurement item or a combination of items that causes an effect occurs, a process corresponding to the measurement item or a combination of the items may be added.

Hereinafter, as a first embodiment of the present invention,
An example in which the analyzer shown in FIG. 1 is configured as an immune analyzer that performs an immune analysis according to the flowchart shown in FIG. 2 will be described. The effect of carryover on the next sample and subsequent samples that occurs in the immunoanalyzer differs depending on the cleaning ability of the sample dispensing nozzle, the cleaning nozzle, and the like. Here, when the measurement item is AFP, the carry-over effect appears only in the next test of the next sample,
When the concentration of AFP exceeds a certain concentration,
It is assumed to be constant at 1.5 ng / ml.
In the case of EA as well, the effect of carry-over appears only in the next test, and the amount of contamination is 0.5 ng / ml at maximum.
In the case of CA19-9, the influence is exerted until the next test, and the contamination amount is up to 8 ng / ml in the next test and up to 3 in the next test.
ng / ml. When the measurement item is a tumor marker-related antigen, no carryover is recognized for items other than the above.

In this embodiment, as a carry-over detection reexamination logic, a worksheet is created as described with reference to FIG.
Based on the worksheet, a specific measurement item of a specific sample is registered in the retest list according to the flowchart described in FIG. 5, and the retest process is automatically performed.

That is, in order to create a worksheet prior to the start of the analysis operation, AFP, CE are set as items Xa that may cause carry-over in advance.
A, CA19-9 are set. Next, set each item X
a, AFP, CEA, and CA19-9 are items Xb that may be affected by carryover.
Set each of the three items. After that, set each item X
For b, “1” is set for AFP and CEA, and “2” is set for CA19-9, as the test order α affected by the sample showing a high value abnormality.

Next, for each set item Xb, a value that can fluctuate when affected by carryover is set. Here, for the AFP, “+
0.8 to +1.5 ", and for CEA," +0.3 to +0.5 "in the first test, and CA19-9
For the first test, "+4.0 to +8.0"
“+2.0 to +3.0” is set for each test. Through the above input processing, a worksheet as shown in FIG. 8 is created and stored in the storage unit 14 (see FIG. 1).

Thereafter, in the actual analysis operation, if a high value abnormality is detected, registration processing to the retest list is performed according to the flowchart shown in FIG. 5, and a retest target warning is added to the measured value of the registered test measurement item. A mark is added and re-inspection is performed automatically.

As a specific example, AFP, CA12
The following describes three measurement patterns in a state where four measurement items of 5, CEA, and CA19-9 are registered. Specific example 1: For each sample, measurement of four registered items was performed by AFP, CA125, CEA, and CA19-9.
In the order of I. Re-examination list-up processing when high value abnormality is detected I-1.1 When only AFP of sample has high value abnormality In this case, since α = 2 from the worksheet in FIG.
The retest target is up to the second test of the second sample. Here, the AFP of the first test of the second sample is registered in Xb of FIG. 8 and satisfies the measurement of the first test that affects the AFP, and the AFP of the first sample is not a normal measurement. The measurement of this AFP is registered in the retest list. In addition, CA125 of the second test of the second sample is Xb in FIG.
Is not registered during the test and will be excluded from retesting. Therefore, in this case, only the AFP of the second sample is registered in the retest list as a retest target.

I-2.1 When only the CEA of the sample has a high value abnormality In this case, since α = 2 from the worksheet of FIG.
The retest target is up to the second test of the second sample. Here, the AFP of the first test of the second sample is registered in Xb in FIG. 8 and satisfies that the AFP is the measurement of the first test in which the AFP is affected. Therefore, this AFP measurement is excluded from the retest target. In addition, CA125 of the second test of the second sample
Are not registered in Xb of FIG. 8 and are excluded from the retest target. Therefore, in this case, it is determined that there is no item requiring re-examination, and nothing is registered in the re-examination list.

I-3.1 Case Where Only CA19-9 of the First Sample Has a High Value Abnormality In this case, as in the case of the above 1-2, it is determined that there is no item requiring retesting as a result. Nothing is registered in the reexamination list.

I-4.1 When Only CA125 of the First Sample Has High Value Abnormality In this case, since CA125 is not registered in Xa of FIG. 8, it is determined that there is no item requiring retest, and Nothing is registered in the examination list.

II. Provision of information from retest measurement values II-1 In the above case I-1, let M be the first measurement value of AFP of the second sample measured and N be the measurement value by retest. In this case, the value that fluctuates due to carry over of the AFP is “+0.8 to +0.8” from the worksheet in FIG.
1.5 ”, (NM) is 0.8 ≦ (N−
When M) ≦ 1.5, M is affected by carryover, N can be determined to be a true value, and the AFP of a sample showing a high value abnormality is 10,000 ng / ml or more. You can see that there is. (N−M) is −0.8 ≦ (N−M) <
In the case of 0.8, it can be determined that M is not affected by carry-over, and AF of a sample showing a high value abnormality is determined.
It can be seen that P is less than 10,000 ng / ml. (N-
When (M) is (NM) <-0.8, it is considered that the sample fluctuated due to the influence of evaporation or the like before the retest measurement.

Specific Example 2: The first sample is CA19-9 by the random access method in which the items to be measured are different for each sample.
In the case where CA125 is measured for the second sample and AFP and CEA are sequentially measured for the third sample, the CA of the first sample is measured.
When an abnormally high value is detected in the measurement of 19-9. Re-examination list-up processing when high value abnormality is detected In this case, the measurement order is CA19-9, CA125, AF
Since α = 2 from the worksheet of FIG. 8 in the order of P and CEA, the retest target is up to the AFP of the first test of the third sample. Here, CA125 of the first test of the second sample
Is not registered in Xb in FIG. 8 and is therefore excluded from the retest. The AFP of the third sample is registered in Xb in FIG. Is not satisfied, and is therefore excluded from retesting. Therefore, in this case, it is determined that there is no item requiring re-examination, and nothing is registered in the re-examination list.

Specific Example 3: The first sample uses AFP and the second sample uses the random access method in which the items to be measured are different for each sample.
In the case where CA125 is measured for the sample and CA19-9 and CEA are measured for the third sample in sequence, the AF of the first sample is measured.
When an abnormally high value is detected in the measurement of P. I. Re-examination list-up processing when high value abnormality is detected In this case, the measurement order is AFP, CA125, CA19-
9 and CEA in the order of α = 2 from the worksheet of FIG.
Up to -9. Here, CA of the first test of the second sample
Since 125 is not registered in Xb of FIG. 8, it is excluded from the retesting target, and the third sample CA19-9 is registered in Xb of FIG. Since the measurement is within the eye, and the measurement is not performed on the first sample, it is registered as a retest target. Therefore, in this case, only CA19-9 is registered in the retest list as a retest target.

II. Provision of information from retest measurement values In this case, the same information as that described in II-1 of the specific example 1 is obtained. However, in this case, the value that fluctuates due to carry-over of CA19-9 is “+2.0 to +3.0” according to the fluctuation value (α = 2) of the second test in FIG.

In the second embodiment of the present invention, the analyzer shown in FIG. 1 is configured as a biochemical analyzer for performing an analysis according to the flowchart shown in FIG. 3, and is similar to the first embodiment. Only necessary retest items are extracted and rechecked automatically.

That is, in recent biochemical analyzers, AFP and CEA are measured using the latex method.
In this case, if the liver function item of biochemistry shows a high value,
AFP and CEA are also expected to be high, and vice versa. Therefore, AFP, C for the next sample with high GPT or GOT and the next sample with high CRP
The effects of carryover are sufficiently estimated for EA and CRP.

Therefore, in the second embodiment of the present invention,
In the same manner as in the first embodiment, a worksheet for extracting retest items by carryover is created, and when a high value abnormal sample is detected, a specific measurement item of a specific sample is determined based on the worksheet. Is registered in the retest list,
A re-inspection process is performed automatically.

In the third embodiment of the present invention, the reaction table 2 shown in FIG. While performing dispensing, sample dispensing, etc., a desired measurement item is analyzed by a late assay method in which photometry is performed every time the light passes through the photometric unit 7, and the high value abnormality detecting means 15 detects a high value abnormality using prozone detection logic. An immunoanalyzer or a biochemical analyzer is configured to perform detection, and only necessary retest items are extracted and automatically retested as in the above-described embodiment.

Here, the prozone phenomenon occurs when the substance to be measured is extremely excessively present in the test solution, and has a higher value among the measurements usually indicated as abnormal high values. In addition, the effect of carry-over occurs in a sample which can be said to be extremely high among abnormal high values. Therefore, for example, if only the next test of a sample in which a prozone is detected is extracted as a retest target and retested, the result of the retest does not actually have the effect of carryover. Can be effectively excluded.

[0051]

According to the present invention, a test that is not affected by carry-over can be reliably excluded from the retest target, so that waste of the test can be reduced, and thus the test time can be reduced and the test cost can be reduced. Can be reduced. In addition, since a test that could not be detected until now can be reliably extracted even if there is an influence of carry-over, the reliability of the test can be improved and a test error can be effectively prevented.

[Brief description of the drawings]

FIG. 1 is a diagram schematically showing the configuration of an analyzer according to the present invention.

FIG. 2 is a flowchart showing an example of a basic analysis operation when the analyzer shown in FIG. 1 is configured as an immune analyzer.

FIG. 3 is a flowchart showing an example of a basic analysis operation when the analyzer shown in FIG. 1 is configured as a biochemical analyzer.

FIG. 4 is a diagram for explaining an example of a worksheet creation process in the analyzer according to the present invention.

FIG. 5 is a flowchart showing a registration process to a re-examination list based on the worksheet of FIG. 4;

FIG. 6 is a diagram for explaining another example of the worksheet creation processing in the analyzer according to the present invention.

FIG. 7 is a flowchart showing a registration process for a re-examination list based on the worksheet of FIG. 6;

FIG. 8 is a diagram for explaining a worksheet created in the first embodiment of the present invention.

FIG. 9 is a graph showing the relationship between the sample concentration of AFP and the carry-over amount for the next test.

[Explanation of symbols]

 DESCRIPTION OF SYMBOLS 1 Reaction container 2 Reaction table 3 Reagent dispensing part 3a Nozzle washing tank 4 Sample dispensing part 4a Nozzle washing tank 5 Stirring part 5a Washing tank 6 Washing part 6a Washing tank 7 Photometric part 8 Reaction container exchange part 11 CPU 12 Output part 13 Input unit 14 Storage unit 15 High value abnormality detection means

Claims (4)

[Claims] 1. An analyzer for automatically and sequentially analyzing desired measurement items for a plurality of specimens, comprising: a high value abnormality detecting means for detecting a high value abnormality from sequentially obtained measurement values; and a high value abnormality by the high value abnormality detecting means. When is detected,
A control unit for controlling an analysis operation so as to perform a retest up to a preset number of tests on the samples subsequent to the sample. 2. The analyzer according to claim 1, wherein the number of tests for performing the retest is set according to a measurement item. 3. The analyzer according to claim 1, wherein the retest is performed on a measurement item in which a high value abnormality is detected, or on the measurement item and a measurement item related thereto. An analyzer, characterized in that: 4. The analyzer according to claim 1, wherein the measurement value of the next sample of the same measurement item as the measurement item in which the high value abnormality is detected and the measurement of the next sample in the retest are performed. An analyzer that determines a sample state including the presence or absence of carry-over based on a value and a reference value for the measurement item.